International Clinical Trial: A Multicenter Phase 3 Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Dienogest in Women with Painful Symptoms Associated with Adenomyosis

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132541) titled 'A Multicenter Phase 3 Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Dienogest in Women with Painful Symptoms Associated with Adenomyosis' on Sept. 15.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Peking Union Medical College Hospital

Condition: Painful Symptoms Associated with Adenomyosis

Intervention: Placebo group:Placebo

Recruitment Status: Not Recruiting

Phase: 3

Date of First Enrollment: 2023-06-07

Target Sample Size: Placebo group:80;Dienogest group:80;

Countries of Recruitment: China

To know more, visit https://www.chictr.or...